ASML vs CLS

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.

Celestica Inc. exhibits a stark divergence between its explosive growth metrics and its deterministic health indicators, highlighted by a weak Piotroski F-Score of 3/9. While the company delivers exceptional revenue (43.6%) and earnings (77.7%) growth with a consistent track record of beats, the current price of $410.21 represents a massive premium over both the Graham Number ($55.82) and the growth-based Intrinsic Value ($211.81). The combination of bearish insider selling and a weak technical trend suggests the stock may be overextended despite strong analyst sentiment. Consequently, the valuation risk currently outweighs the growth momentum.